SPT Labtech, a global leader in the design and development of laboratory automation and fluid handling solutions, and Alithea Genomics, a pioneer in RNA sequencing and large-scale transcriptomics, today announced a collaboration to provide an automated solution for single-cell transcriptomics.
The collaboration incorporates Alithea Genomics’ ultra-sensitive single-cell RNA-seq technology, MERCURIUS™ FLASH-seq, with SPT Labtech’s firefly® fluid handling platform, creating a scalable and reproducible workflow for transcriptional research. The automated workflow is readily available to customers worldwide through the application support teams of SPT Labtech and Alithea Genomics.
Single-cell transcriptomics is a rapidly growing field that is driving advances in cell biology, immunology, and drug discovery. However, many workflows remain limited by manual library preparation steps, which can introduce variability and performance limitation. This collaboration directly addresses this bottleneck by combining Fifly’s precision low-volume dispensing with Alithea Genomics’ scalable RNA-sequencing chemistry, improving reproducibility, throughput and accessibility for single cell studies. As the demand for higher throughput and cost-effective single-cell sequencing increases, the ability to automate sensitive RNA-seq protocols is becoming essential for both academic and research environments.
Alithea Genomics has earned recognition for transforming RNA sequencing with its scalable and cost-effective solutions. MERCURIUS FLASH-seq, a novel single-cell RNA-seq protocol, offers gene detection sensitivity in ultra-low-input samples and single cells.
Our mission has always been to make high-throughput, high-quality RNA-seq accessible and scalable for any laboratory. By combining MERCURIUS FLASH-seq and MERCURIUS Total DRUG-seq with SPT Labtech’s firefly, we remove key bottlenecks in library preparation workflows. This collaboration simplifies complex processes, reduces costs and enables researchers to focus on discovery.”
Riccardo Dainese, CEO and co-founder of Alithea Genomics;
Morten Frost, Chief Commercial Officer of SPT Labtech, commented: “This collaboration represents a step toward broader automation of complex RNA workflows, supporting the increasing integration of transcriptomics into translational and clinical research. By implementing this workflow in firefly, laboratories can achieve a new level of efficiency, reproducibility, and efficiency. firefly’s modular architecture supports results in a variety of experimental and large-scale needs.”
